Drug name: Oncofid-​P


Related CSCTT Targets

CD44 [ref.1]P16070

Hyaluronic acid

Cas.no PubChem ID
9067-32-7 3084049
Known Target
CD44 antigenP16070
Intercellular adhesion molecule 1P05362
Hyaluronan mediated motility receptorO75330
Structure
...
Introduction
ONCOFID-P is a new HA-paclitaxel bioconjugate for intraperitoneal treatment of ovarian cancer. HA-drug bioconjugates may present a markedly enhanced selectivity for cancerous cells, while exhibiting improved water solubility relative to the parent drug. Such as ONCOFID-P proved to be more eVective than free IP paclitaxel, and exhibited similar side effects at a two-fold higher dose.

Paclitaxel

Cas.no PubChem ID
33069-62-4 36314
Known Target
Tubulin beta-1 chainQ9H4B7
Apoptosis regulator Bcl-2P10415
Nuclear receptor subfamily 1 group I member 2O75469
Microtubule-associated protein 4P27816
Microtubule-associated protein 2P11137
Microtubule-associated protein tauP10636
Structure
...
Introduction
Paclitaxel is a mitotic inhibitor used in cancer chemotherapy. Paclitaxel is approved for ovarian, breast and lung, bladder, prostate, melanoma, esophageal, and other types of solid tumor cancers as well as Kaposi's sarcoma.

Reference

  • [1] Hyaluronic acid-paclitaxel: effects of intraperitoneal administration against CD44(+) human ovarian cancer xenografts. De Stefano, I., et al. (2011).Cancer Chemother Pharmacol. 68(1):107-16.
    20848284. [ 20848284 ]

Back to top